Tag Archives: Oncology

Pharma Seizes Latin American Opportunities

Approximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years. And with untapped potential identified in countries across the region, companies are expected to seize upon further opportunities to drive future growth, says a new report from GlobalData.
Posted in Emerging Markets, Market Access | Also tagged , , , , , | Leave a comment

Three Capabilities You Must Build Today to
Ensure Market Access Tomorrow

By Howard Deutsch, Associate Principal, ZS Associates (Sponsored Content) Oncology-market access doesn’t “just happen” anymore. As competition in the U.S. health-care market only continues to intensify, oncology-drug companies will need a good corporate strategy to ensure physician uptake and payer coverage of therapies. Having strong clinical data isn’t enough, especially as stakeholders grow ever more […]
Posted in Strategy | Also tagged , | Leave a comment

Five Ways for Pharma to Read Between the Tweets

Sharon Karlsberg, Principal, ZS Associates (Sponsored Content) While buzz on Twitter will never outweigh critical data in a peer-reviewed publication, social media is becoming an important part of our industry’s dialogue. The oncology market is no exception, as insight gleaned from recent Twitter traffic and trends reveals.
Posted in Strategy | Also tagged | 1 Comment

Winning Pharma's Super Conferences

by Stan Bernard and Janet Wells Like the Super Bowl, pharma companies are winning major congresses by using competitive conference techniques to generate brand buzz and corporate recognition. Each year, thirty-two National Football League teams compete to win the Super Bowl, the ultimate U.S. team sport championship. Simultaneously, dozens of major companies are also competing […]
Posted in Advertising, Agency Insight, Marketing, Meetings, Strategy | Also tagged , , , , , , | 1 Comment

CEO Interview: Harvey Berger, Ariad Pharmaceuticals

Eight months into the launch of its first approved drug – Iclusig (ponatinib), a small molecule therapy indicated for two rare forms of leukemia – Ariad Pharmaceuticals’ principal founder and CEO Harvey Berger says doing it all, from discovery to global commercialization, is the company’s path to sustainability and the way to take on Big […]
Posted in Biotech, Europe, Gene therapy, Global, leadership, Market Access, Marketing, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta